Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | GNRHR | P30968 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | BACE1 | P56817 | 1/20 | 0.30 |
| ▸ | KDM5A | P29375 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29243602 | 0.94 | KDM5A (0.34) | MAPK1GNRHRCYP2D6PKMCYP2C19 | |
| SCHEMBL29243445 | 0.94 | KDM5A (0.34) | MAPK1GNRHRCYP2D6PKMCYP2C19 | |
| SCHEMBL29586441 | 0.94 | KDM5A (0.34) | MAPK1GNRHRCYP2D6PKMCYP2C19 | |
| SCHEMBL24424114 | 0.94 | KDM5A (0.34) | MAPK1GNRHRCYP2D6PKMCYP2C19 | |
| SCHEMBL24424115 | 0.94 | KDM5A (0.34) | MAPK1GNRHRCYP2D6PKMCYP2C19 | |
| SCHEMBL29585776 | 0.94 | KDM5A (0.34) | MAPK1GNRHRCYP2D6PKMCYP2C19 | |
| SCHEMBL24424120 | 0.94 | KDM5A (0.34) | MAPK1GNRHRCYP2D6PKMCYP2C19 | |
| SCHEMBL24424121 | 0.94 | KDM5A (0.34) | MAPK1GNRHRCYP2D6PKMCYP2C19 | |
| SCHEMBL29243568 | 0.94 | KDM5A (0.34) | MAPK1GNRHRCYP2D6PKMCYP2C19 | |
| SCHEMBL29243446 | 0.94 | KDM5A (0.34) | MAPK1GNRHRCYP2D6PKMCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230062861-A1 | PPARg MODULATORS AND METHODS OF USE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2023-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230062861-A1 | PPARg MODULATORS AND METHODS OF USE | PPARG, PPARA, PPARD | MAPK1 1659/4885GNRHR 610/4885CYP2D6 277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.